Stable insulin formulations

Details Stable insulin formulations Stable insulin formulations

2005-06-14

2005-06-14

Tate, Christopher (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S004300, C514S012200, C530S303000, C530S304000, C530S305000

Reexamination Certificate

active

06906028

ABSTRACT:
The present invention provides a monomeric insulin analog formulation stabilized against aggregation in which the buffering agent is either TRIS or arginine. The stable formulations of the present invention are useful for treating diabetes, and are particularly advantageous in treatment regimes requiring lengthy chemical and physical stability, such as, in continuous infusion systems.

REFERENCES:
patent: 4472385 (1984-09-01), Brange et al.
patent: 4476118 (1984-10-01), Brange et al.
patent: 4783441 (1988-11-01), Thurow
patent: 4839341 (1989-06-01), Massey
patent: 5461031 (1995-10-01), DeFelippis
patent: 5474978 (1995-12-01), Bakaysa et al.
patent: 5514646 (1996-05-01), Chance et al.
patent: 5547929 (1996-08-01), Anderson et al.
patent: 5650486 (1997-07-01), DeFelippis
patent: 5658878 (1997-08-01), Backstrom et al.
patent: 6034054 (2000-03-01), DeFelippis et al.
patent: 214 826 (1987-03-01), None
patent: 0 735 048 (1996-10-01), None
patent: 1285023 (1972-08-01), None
patent: WO 87/06137 (1987-10-01), None
patent: WO 99/34821 (1999-07-01), None
J. Brange, et al., “Chemical stability of insulin,”Acta Pharm. Nord.4(3) 149-158 (1992), Swedish Pharmaceutical Press, Stockholm, Sweden.
R. Quinn, et al., “Minimizing the aggregation of neutral insulin solutions”Journal of Pharmaceutical Sciences72(12), Dec. 1983, John Wiley & Sons, Hoboken, New Jersey.
Brems, et al.,Protein Engineering, 6:527-533 (1992), Oxford University Press, New York, New York.
Brange, et al.,Current Opinion in Structural Biology, 1:934-940 (1991), Elsevier Science Inc., New York, New York.
Patent Abstract of Japan, vol. 006, No. 143, C-117, Aug. 3, 1982 and JP 57 067548 A (Shionogi & Co. Ltd.), Apr. 24, 1982, refers to preparation comprising insulin analogues in the presence of glycerine, trishydroxy-methylaminomethane, ZnCl2 and cresol-phenol as an antiseptic.
Markussen Jan, Damgaard U, Jorgensen KH, Sorensen, Thim L, “Human Monocomponent Insulni”,Acta. Med. Scand., Suppl., No. 671, pp. 99-105, 1983, Almquist and Wiksell, Stockholm, Sweden.
Pending claims of Application No. 09/450,794 (3 pages).

Affiliated with

Also associated with

Rating

Stable insulin formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable insulin formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable insulin formulations will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3513485